Based on current International Myeloma Working Group (IMWG) consensus of MM response criteria, MRD in bone marrow (BM) should be detected by sensitive, validated methods either by MFC, including next-generation flow cytometry (NGF) or by NGS, with a sensitivity level of at least 10−5 [18]. This evidence concerns the gene NGF and Miyoshi myopathy.